Marcy l’Étoile, France, January 13, 2025 – bioMérieux, a world leader in the field in vitro diagnostics, today announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, USA, from January 13 to 16, 2025.
Pierre Boulud, Chief Executive Officer of bioMérieux, will give a presentation on January 14, 2025, at 5:15 pm PT (02:15 am CET). A Q&A session will follow the presentation.
On this occasion, Pierre Boulud, will present an overview of bioMérieux together with the main drivers of its strategic plan, GO•28, presented last April, during the Capital Markets Day. The ambition is to deliver a profitable and sustainable growth with a +7% CAGR(1) organic sales growth over the period 2024 / 2028 and an increase in CEBIT(2) margin from 16.6% of sales in 2023 to 20% in 2028 at constant exchange rates and perimeter.
In addition, Pierre Boulud will provide an update on installations of BIOFIRE® and SPOTFIRE® in Q4 2024, respectively +500 net units and +900 units, and present bioMérieux’s recent acquisition of SpinChip, a Norwegian start-up dedicated to point-of-care immunoassays.
bioMérieux's presentation (in English) will be broadcasted live (audio only) using the following link: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58370-biomerieux/webcast?gpu_only=true&kiosk=true
The slides of the presentation will be made available on the company's website: www.biomerieux.com.
(1) CAGR: Compound Annual Growth Rate
(2) CEBIT: Contributive operating income before non-recurring items: operating income before non-recurring items, excluding items relating to the amortization and impairment of intangible assets related to acquisitions and acquisition-related costs.
Read the full press release
- Filename
- PR_bioMerieux_JP_Morgan_Healthcare_Conference_20250113.pdf
- Size
- 181 KB
- Format
- application/pdf